Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Hot Stocks Free for All ! » BIOM up 135%. maybe next ALT.

 - UBBFriend: Email this page to someone!    
Author Topic: BIOM up 135%. maybe next ALT.
ththf
Member


Rate Member
Icon 6 posted      Profile for ththf     Send New Private Message       Edit/Delete Post   Reply With Quote 
this is only a gamble on ALT.

do your dd

Actually I am pumping ALT as well as BIOM.

I have both of them

[This message has been edited by ththf (edited December 04, 2004).]


Posts: 742 | Registered: Dec 2003  |  IP: Logged | Report this post to a Moderator
ya ya
Member


Rate Member
Icon 1 posted      Profile for ya ya         Edit/Delete Post   Reply With Quote 
THTHF - Did you get your user name from the stock - I own some shares of THTHF
Posts: 1326 | From: Providence,RI,USA | Registered: May 2004  |  IP: Logged | Report this post to a Moderator
glassman
Member


Icon 1 posted      Profile for glassman     Send New Private Message       Edit/Delete Post   Reply With Quote 
this is BIG
Posts: 36378 | From: USA | Registered: Sep 2003  |  IP: Logged | Report this post to a Moderator
pennyearned
Member


Rate Member
Icon 1 posted      Profile for pennyearned     Send New Private Message       Edit/Delete Post   Reply With Quote 
Tickers going NUTS on this one.
Posts: 106 | Registered: Aug 2004  |  IP: Logged | Report this post to a Moderator
yes
New Member


Member Rated:
5
Icon 1 posted      Profile for yes     Send New Private Message       Edit/Delete Post   Reply With Quote 
Press Release Source: Biomira Inc.

Update of BLP25 Liposome Vaccine Phase IIb trial shows stage IIIB patients who received vaccine have not yet reached median survival 23 months post accrual
Friday December 3, 6:01 am ET
Data to be Submitted for Presentation and Publication

EDMONTON, Alberta and DARMSTADT, Germany, Dec. 3 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq:BIOM - News; TSX:BRA - News) and Merck KGaA of Darmstadt, Germany, announced today that the updated survival analysis of their completed Phase IIb study of the investigational immunotherapy BLP25 Liposome Vaccine (L-BLP25), used in this trial for the treatment of non-small cell lung cancer (NSCLC), showed that a median survival in the pre-stratified subset of locoregional Stage IIIB patients on the vaccine arm has still not been reached. Lung cancer is the leading cause of cancer-related mortality for both sexes in North America.

ADVERTISEMENT
An exploratory survival update of the randomized, open-label Phase IIb trial of L-BLP25 in 171 men and women with NSCLC, whose disease was stable or who had responded to treatment following first-line standard chemotherapy or a combination of standard chemotherapy and radiotherapy was just completed. This analysis showed that in the subset of men and women with locoregional Stage IIIB disease (locally advanced and unresectable) who received L-BLP25, a survival median has not yet been reached 23 months following the enrollment of the last patient into the trial.

"We believe that the results to date are very exciting, and we look forward to presenting the data," said Alex McPherson, MD, PhD, President and CEO of Biomira Inc.

The study's investigators plan to submit the updated survival data from this analysis for presentation at an upcoming scientific meeting and for publication in a peer reviewed medical journal.

"The data are encouraging and support plans for Merck KGaA and its U.S. subsidiary, EMD Pharmaceuticals, to continue the collaborative development of L-BLP25 with Biomira," said Bernhard Ehmer, MD, Vice President and Head of Merck's Oncology Business Area. "In the new year, the companies plan to discuss a Phase III multinational registration trial with regulatory authorities."

In preparation for a potential multinational registration trial, Biomira is already scheduling for the manufacture of new vaccine supplies. These supplies will incorporate manufacturing changes intended to secure the future commercial supply of the vaccine. Scheduling these changes now ensures that the resulting pivotal data will be considered representative of the safety and effectiveness of the commercial supply of the vaccine. To assure the successful initiation of a pivotal trial, a comparability plan is now being developed.

L-BLP25

L-BLP25 is a synthetic MUC1 peptide vaccine. L-BLP25 incorporates a 25-amino acid sequence of the MUC1 cancer mucin, encapsulated in a liposomal delivery system. The liposome enhances recognition of the cancer antigen by the immune system and facilitates better delivery. L-BLP25 is designed to induce an immune response to cancer cells.

About Lung Cancer

In 2004, approximately 174,000 new cases of lung cancer will be diagnosed in the U.S. - 54 per cent of them in men and 46 per cent in women. Approximately 160,000 people will die of this disease in the U.S. alone in 2004. In Canada, the mortality percentages are slightly higher for men - 57 per cent of deaths from lung cancer will occur in men and 43 per cent will be in women. NSCLC accounts for approximately 75 to 80 per cent of all primary lung cancers. At the time of diagnosis, only 25 per cent of patients are potentially curable by surgery.

The Companies

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. Biomira's commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy. We are The Cancer Vaccine People(TM).

Merck is a global pharmaceutical and chemical company with sales of EUR 7.2 billion in 2003, a history that began in 1668, and a future shaped by 28,300 employees in 56 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 74 per cent interest and free shareholders own the remaining 26 per cent. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917. Merck KGaA has built a strategic oncology portfolio by developing and in-licensing product candidates in four areas - monoclonal antibodies, therapeutic vaccines, immunocytokines and angiogenesis inhibitors.

EMD Pharmaceuticals Inc., the U.S. affiliate of Merck KGaA, is a fully integrated pharmaceutical company with an initial emphasis on launching new products in oncology. Located in Durham, N.C., EMD focuses on meeting patient and physician needs with pioneering pharmaceutical products and services.

Except for historical information contained herein, this release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties surrounding the efficacy of L-BLP25 to treat men and women with NSCLC, which may include risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include the risk that additional trials may not demonstrate the safety and efficacy required to satisfy the regulatory authorities, the risk that the Company may lack the financial resources and access to capital to fund the required clinical trials, or that it will elect to conduct such additional trials, and other matters required to bring products to market, the uncertainties as to when, if at all, the regulatory authorities will agree to discuss the trial results with the Company and whether they will approve the product and manufacturing facilities, the need to establish and scale-up manufacturing processes, dependence on the efforts of third parties, including suppliers and collaborators, dependence on intellectual property rights and the effectiveness thereof, difficulties or delays in manufacturing products, and regulatory developments involving products and manufacturing facilities. For more detailed information on the risks and uncertainties associated with the Company's product candidates and other activities see the Company's periodic reports filed with the applicable securities regulatory authorities in Canada and the United States Securities and Exchange Commission. The Company assumes no obligation to update any forward-looking statements.


Source: Biomira Inc.


Posts: 0 | Registered: A Long Time Ago!  |  IP: Logged | Report this post to a Moderator
glassman
Member


Icon 1 posted      Profile for glassman     Send New Private Message       Edit/Delete Post   Reply With Quote 
level 2 is triggering my epliptic seizures...LOL
Posts: 36378 | From: USA | Registered: Sep 2003  |  IP: Logged | Report this post to a Moderator
glassman
Member


Icon 1 posted      Profile for glassman     Send New Private Message       Edit/Delete Post   Reply With Quote 
i wonder when the large blocks will start trading?

Posts: 36378 | From: USA | Registered: Sep 2003  |  IP: Logged | Report this post to a Moderator
ththf
Member


Rate Member
Icon 10 posted      Profile for ththf     Send New Private Message       Edit/Delete Post   Reply With Quote 
actually I mean you should pay more attention to ALT 's report soon.

ALT always make a sudden surge every year as its study. And ALT always go up after BIOM

Let's see if it will up in next week.

Don't listen to my BS. study it first.


Posts: 742 | Registered: Dec 2003  |  IP: Logged | Report this post to a Moderator
mryj2000
Member


Member Rated:
4
Icon 1 posted      Profile for mryj2000     Send New Private Message       Edit/Delete Post   Reply With Quote 
BIOM very strong. Got some this morning.

first target is 5.0. maybe more up after Tuesday news.


Posts: 311 | Registered: Dec 2003  |  IP: Logged | Report this post to a Moderator
glassman
Member


Icon 1 posted      Profile for glassman     Send New Private Message       Edit/Delete Post   Reply With Quote 
it sure did take its time before it got legs this morning....i think 5$ is conservative....
Posts: 36378 | From: USA | Registered: Sep 2003  |  IP: Logged | Report this post to a Moderator
ththf
Member


Rate Member
Icon 1 posted      Profile for ththf     Send New Private Message       Edit/Delete Post   Reply With Quote 
ALT up 10% today. Sell it out.

my profit out. 15% gain since my recommendation.


Posts: 742 | Registered: Dec 2003  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share